InventisBio licenses lung cancer drug D-0316 to Betta Pharma in RMB230m deal
In a significant development within the pharmaceutical industry, Shanghai-based InventisBio has entered into a strategic partnership with Betta Pharmaceuticals Co., Ltd. to co-develop the promising lung cancer drug D-0316. Under this agreement, InventisBio has out-licensed the rights to D-0316 in China, Hong Kong, and Taiwan to Betta Pharmaceuticals Co., Ltd. in a deal valued at […]